Discovery of BGB-8035, a Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase for B-Cell Malignancies and Autoimmune Diseases.

Bruton's tyrosine kinase (BTK) plays an essential role in B-cell receptor (BCR)-mediated signaling as well as the downstream signaling pathway for Fc receptors (FcRs). Targeting BTK for B-cell malignancies by interfering with BCR signaling has been clinically validated by some covalent inhibitors, but suboptimal kinase selectivity may lead to some adverse effects, which also makes the clinical development of autoimmune disease therapy more challenging. The structure-activity relationship (SAR) starting from zanubrutinib (BGB-3111) leads to a series of highly selective BTK inhibitors, in which BGB-8035 is located in the ATP binding pocket and has similar hinge binding to ATP but exhibits high selectivity over other kinases (EGFR, Tec, etc.). With an excellent pharmacokinetic profile as well as demonstrated efficacy studies in oncology and autoimmune disease models, BGB-8035 has been declared a preclinical candidate. However, BGB-8035 showed an inferior toxicity profile compared to that of BGB-3111.

[1]  D. Nomura,et al.  Advances in covalent drug discovery , 2022, Nature Reviews Drug Discovery.

[2]  M. Mingueneau,et al.  Discovery and Preclinical Characterization of BIIB091, a Reversible, Selective BTK Inhibitor for the Treatment of Multiple Sclerosis. , 2021, Journal of medicinal chemistry.

[3]  D. Fabbro,et al.  Trends in kinase drug discovery: targets, indications and inhibitor design , 2021, Nature Reviews Drug Discovery.

[4]  Sohita Dhillon.  Orelabrutinib: First Approval , 2021, Drugs.

[5]  M. Dimopoulos,et al.  A RANDOMIZED PHASE 3 TRIAL OF ZANUBRUTINIB VERSUS IBRUTINIB IN SYMPTOMATIC WALDENSTRÖM MACROGLOBULINEMIA:THE ASPEN STUDY. , 2020, Blood.

[6]  Sohita Dhillon.  Tirabrutinib: First Approval , 2020, Drugs.

[7]  Cuining Zhang,et al.  Nonclinical Safety Assessment of Zanubrutinib: A Novel Irreversible BTK Inhibitor , 2020, International journal of toxicology.

[8]  E. G. Funhoff,et al.  Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase. , 2020, Journal of medicinal chemistry.

[9]  Zhiwei Wang,et al.  Discovery of Zanubrutinib (BGB-3111), a Novel, Potent and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase. , 2019, Journal of medicinal chemistry.

[10]  M. Camps,et al.  Discovery of Evobrutinib: An Oral, Potent and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases. , 2019, Journal of medicinal chemistry.

[11]  Michael A. Galella,et al.  Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton's Tyrosine Kinase (BTK). , 2019, Journal of medicinal chemistry.

[12]  T. Kinoshita,et al.  The effect of Bruton's tyrosine kinase (BTK) inhibitors on collagen‐induced platelet aggregation, BTK, and tyrosine kinase expressed in hepatocellular carcinoma (TEC) , 2018, European journal of haematology.

[13]  S. Watson,et al.  Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VI , 2018, Haematologica.

[14]  A. Schlessinger,et al.  Redefining the Protein Kinase Conformational Space with Machine Learning. , 2018, Cell chemical biology.

[15]  Adam R. Johnson,et al.  Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development. , 2018, Journal of medicinal chemistry.

[16]  J. Funk,et al.  A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton's tyrosine kinase, in healthy volunteers , 2017, British journal of clinical pharmacology.

[17]  Y. Senis,et al.  Src family kinases: at the forefront of platelet activation. , 2014, Blood.

[18]  G. Tortora,et al.  Targeting the epidermal growth factor receptor in solid tumors: focus on safety , 2014, Expert opinion on drug safety.

[19]  Jason M. Edmonds,et al.  Selective Inhibition of BTK Prevents Murine Lupus and Antibody-Mediated Glomerulonephritis , 2013, The Journal of Immunology.

[20]  Juswinder Singh,et al.  Inhibition of Btk with CC-292 Provides Early Pharmacodynamic Assessment of Activity in Mice and Humans , 2013, The Journal of Pharmacology and Experimental Therapeutics.

[21]  B. Melosky.  Supportive care treatments for toxicities of anti-egfr and other targeted agents. , 2012, Current oncology.

[22]  Daigen Xu,et al.  RN486, a Selective Bruton's Tyrosine Kinase Inhibitor, Abrogates Immune Hypersensitivity Responses and Arthritis in Rodents , 2012, Journal of Pharmacology and Experimental Therapeutics.

[23]  Adrian Whitty,et al.  The resurgence of covalent drugs , 2011, Nature Reviews Drug Discovery.

[24]  D. Moras,et al.  Cysteine mapping in conformationally distinct kinase nucleotide binding sites: application to the design of selective covalent inhibitors. , 2011, Journal of medicinal chemistry.

[25]  Brandon J. Bravo,et al.  Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis. , 2011, Nature chemical biology.

[26]  Juswinder Singh,et al.  Targeted covalent drugs of the kinase family. , 2010, Current opinion in chemical biology.

[27]  Jan Delabie,et al.  Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma , 2010, Nature.

[28]  R. Perez-soler,et al.  Skin toxicities associated with epidermal growth factor receptor inhibitors , 2009, Targeted Oncology.

[29]  D. G. Udugamasooriya,et al.  Conformational constraint in protein ligand design and the inconsistency of binding entropy. , 2008, Biopolymers.

[30]  M. Cybulsky,et al.  Dual Functions of Bruton’s Tyrosine Kinase and Tec Kinase during Fcγ Receptor-Induced Signaling and Phagocytosis1 , 2008, The Journal of Immunology.

[31]  L. Honigberg,et al.  Discovery of Selective Irreversible Inhibitors for Bruton’s Tyrosine Kinase , 2007, ChemMedChem.

[32]  Michael S. Cohen,et al.  Structural Bioinformatics-Based Design of Selective, Irreversible Kinase Inhibitors , 2005, Science.

[33]  S. Watson,et al.  Tec regulates platelet activation by GPVI in the absence of Btk. , 2003, Blood.

[34]  Mohamed,et al.  Signalling of Bruton's Tyrosine Kinase, Btk , 1999, Scandinavian journal of immunology.

[35]  T. Kurosaki,et al.  A role for Bruton's tyrosine kinase in B cell antigen receptor-mediated activation of phospholipase C-gamma 2 , 1996, The Journal of experimental medicine.

[36]  R. Holmdahl,et al.  Genes on the X chromosome affect development of collagen‐induced arthritis in mice , 1993, Clinical and Experimental Immunology.